NCT Number: NCT07483476
Minimal residual disease (MRD) monitoring is a key prognostic factor in pediatric acute lymphoblastic leukemia (ALL). Currently, MRD assessment relies mainly on cellular DNA obtained from bone marrow aspirates. Although highly informative, this approach has limitations, including the need for invasive procedures and the fact that it reflects only the bone marrow compartment.
Tumor cells release fragments of genomic DNA into the bloodstream, known as circulating cell-free DNA (cfDNA). In solid tumors, cfDNA analysis has emerged as a valuable non-invasive biomarker for disease monitoring and treatment response. Recent studies have shown that cfDNA is detectable in pediatric ALL.
This study aims to investigate whether plasma cfDNA analysis could represent an alternative or complementary approach to bone marrow-based MRD assessment. cfDNA may better reflect the global tumor burden across the entire body and allow more frequent longitudinal monitoring during treatment.
The primary objective is to assess the correlation between MRD measured in plasma cfDNA and MRD measured in bone marrow cellular DNA at two key timepoints of treatment: the end of induction (Day 29) and the end of consolidation (Day 71-78).
Secondary objectives include evaluating the correlation between peripheral blood cellular DNA and bone marrow MRD, describing clonal evolution using cfDNA throughout treatment and follow-up, exploring the concordance of genomic alterations detected in cfDNA and other biological compartments, assessing the prognostic value of cfDNA MRD for relapse risk and event-free survival, and characterizing cfDNA fragmentome and methylome signatures in patients compared with healthy controls.
The study will include children and adolescents with newly diagnosed ALL treated at two AP-HP pediatric hematology centers, as well as a control cohort of healthy children undergoing HLA typing for sibling stem cell transplant.
Trial opening soon.
Get NotifiedUp to 18 year
All sexes
Observational
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
ALL population
Exclusion criteria
Additional peripheral blood samples will be collected during treatment and follow-up for cell-free DNA analysis. Residual samples from bone marrow and cerebrospinal fluid collected as part of standard clinical care will also be analyzed.
Time frame: Up to day 78 (end of consolidation)
Pearson correlation coefficient between minimal residual disease (MRD) measured in plasma circulating cell-free DNA and MRD measured in bone marrow cellular DNA. Analyses will be performed according to the type of molecular target used for MRD detection (IG/TCR rearrangements, genomic breakpoints, or pathogenic variants).
End of induction (Day 29) and end of consolidation (Day 71-78)
Time frame: At day 29
Pearson correlation coefficient between MRD measured in peripheral blood cellular DNA and MRD measured in bone marrow cellular DNA.
Time frame: At day 78
Pearson correlation coefficient between MRD measured in peripheral blood cellular DNA and MRD measured in bone marrow cellular DNA.
At day 71 to 78
Time frame: At day 1
Mutation profiles of cfDNA across multiple timepoints during treatment and follow-up
Time frame: At day 4
Mutation profiles of cfDNA across multiple timepoints during treatment and follow-up
Time frame: At day 8
Mutation profiles of cfDNA across multiple timepoints during treatment and follow-up
Time frame: At day 15
Mutation profiles of cfDNA across multiple timepoints during treatment and follow-up
Time frame: At day 29
Mutation profiles of cfDNA across multiple timepoints during treatment and follow-up
Time frame: At day 78
Mutation profiles of cfDNA across multiple timepoints during treatment and follow-up At day 71 to 78
Time frame: At end of maintenance
Mutation profiles of cfDNA across multiple timepoints during treatment and follow-up
Time frame: 3 years after remission
Mutation profiles of cfDNA across multiple timepoints during treatment and follow-up
Time frame: At diagnosis
Qualitative and quantitative comparison of genomic alterations detected at diagnosis in cfDNA and in other sample types (bone marrow, cerebrospinal fluid, and other tissues if available)
Time frame: Up to 5 years of follow-up
Association between cfDNA MRD levels and relapse-free survival and event-free survival
Time frame: Up to 5 years
Characterization and comparison of cfDNA fragment size patterns and methylation signatures between patients and healthy controls at diagnosis and during treatment.
At baseline and during treatment
Contact information is provided by the study sponsor or research team.
Jérôme Lambert, MD PhD
CONTACT
+330142499742 ext. +33
Marion Strullu, MD PhD
CONTACT
+330140035388 ext. +33
Assistance Publique - Hôpitaux de Paris
Other
Etude de l'ADN Libre Circulant Dans Les leucémies Aigues Lymphoblastiques de l'Enfant et de l'Adolescent
Acronym: CIRCALL
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07529223
Acute Lymphoblastic Leukemia ALL, Hematologic Diseases
Nice, CHU de Nice, France
View Trial DetailsNCT07113132
Acute Lymphoblastic Leukemia ALL, Chronic Disease
View Trial DetailsNCT07042932
Acute Lymphoblastic Leukemia ALL, Behavior
View Trial DetailsNCT06721598
Acute Lymphoblastic Leukemia ALL, Hematologic Diseases
Moscow, Russia
View Trial Details